Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 09.06.2025 1 AJR Am J Roentgenol 1 Am J Clin Pathol 1 Am J Respir Cell Mol Biol 2 Ann Oncol 3 Ann Surg Oncol 1 Ann Thorac Surg 4 BMC Cancer 2 BMJ 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Res 3 Cancer Sci 1 Carcinogenesis 2 Clin Cancer Res 3 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Int J Cancer 2 J Cancer Res Clin Oncol 2 J Clin Invest 2 J Clin Oncol 1 J Natl Cancer Inst 2 J Thorac Oncol 1 Lancet 22 Lung Cancer 1 Lung Cancer (Auckl) 3 N Engl J Med 1 Nat Med 1 PLoS Biol 1 PLoS One 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ZHU Y
   A Meaningful Stride Toward Precision Staging in Early-Stage Non-Small Cell Lung Cancer.
   AJR Am J Roentgenol. 2025 Jun 4. doi: 10.2214/AJR.25.33332.
   PubMed        
   
   

   
   Am J Clin Pathol

2. WANG B, Wang X, Chang Z, Zhong D, et al
   Primary low-grade salivary gland-type intraductal carcinoma of the lung with CCDC6::RET fusion: Case presentation and literature review.
   Am J Clin Pathol. 2025;163:877-882.
   PubMed         Abstract available
   
   

   
   Am J Respir Cell Mol Biol

3. EVANS JF, Ledwell OA, Tang Y, Rue R, et al
   The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis.
   Am J Respir Cell Mol Biol. 2025;72:643-652.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. DE MARINIS F, Kim TM, Bonanno L, Cheng S, et al
   Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH s
   Ann Oncol. 2025 May 22:S0923-7534(25)00157-7. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
5. BUMA AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, et al
   Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al.
   Ann Oncol. 2025 Jun 2:S0923-7534(25)00198-X. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   

   
   Ann Surg Oncol

6. KHAN AA, Shah SK, Basu S, Alex GC, et al
   Thoracic Adipose Volume is Associated with Occult Nodal Disease and Disease-Free Survival in Females with Clinically Node-Negative Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Jun 3. doi: 10.1245/s10434-025-17485.
   PubMed         Abstract available
   
   
7. WU HL, Yang R, Liang XL, Ma R, et al
   Clinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases.
   Ann Surg Oncol. 2025;32:5051-5062.
   PubMed         Abstract available
   
   
8. TANG WF, Qiu ZB, Chu XP, Zeng YM, et al
   EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass Opacities.
   Ann Surg Oncol. 2025;32:4641-4649.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

9. WU VS, Boutros C, Bassiri A, Jiang B, et al
   Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence.
   Ann Thorac Surg. 2025 May 28:S0003-4975(25)00448.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. SAEED R, McSorley S, Cascales A, McMillan DC, et al
    The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:994.
    PubMed         Abstract available
    
    
11. LI H, Lu Y, Chen H, Li T, et al
    Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients.
    BMC Cancer. 2025;25:999.
    PubMed         Abstract available
    
    
12. TONG X, Zhu T, Ma L, Yang X, et al
    Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor growth and metastasis in non-small cell lung cancer.
    BMC Cancer. 2025;25:1001.
    PubMed         Abstract available
    
    
13. WASILEWSKI D, Shaked Z, Fuchs A, Roohani S, et al
    Re-resection of brain metastases - outcomes of an institutional cohort study and literature review.
    BMC Cancer. 2025;25:973.
    PubMed         Abstract available
    
    

    
    BMJ

14. MA X, Li X
    EGFR-mutated non-small cell lung cancer.
    BMJ. 2025;389:r1154.
    PubMed        
    
    
15. FANG W, Li X, Wang Q, Meng X, et al
    Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.
    BMJ. 2025;389:e085680.
    PubMed         Abstract available
    
    

    
    Cancer

16. PASSIGLIA F, Pepe F, Russo G, Garbo E, et al
    Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer.
    Cancer. 2025;131:e35917.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

17. FENLON J, Van Bibber N, Mahlow J, Yamoah K, et al
    Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.
    Cancer Epidemiol Biomarkers Prev. 2025;34:860-867.
    PubMed         Abstract available
    
    

    
    Cancer Lett

18. YANG Y, Li Z, Yu X, Zheng Y, et al
    WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous recombination deficiency.
    Cancer Lett. 2025;625:217757.
    PubMed         Abstract available
    
    

    
    Cancer Res

19. WANG Y, Meraz IM, Qudratullah M, Kotagiri S, et al
    Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.
    Cancer Res. 2025;85:1997-2013.
    PubMed         Abstract available
    
    

    
    Cancer Sci

20. HUANG J, Yuan Y, Guo L, Xia G, et al
    The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
    Cancer Sci. 2025;116:1550-1564.
    PubMed         Abstract available
    
    
21. ZHANG Y, Xu Y, Jin H, Liu T, et al
    Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:1648-1660.
    PubMed         Abstract available
    
    
22. HONGU T, Sarenqiqige, Shandan, Kusunoki H, et al
    Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing SERPINE1 at Breast Cancer Metastatic Sites.
    Cancer Sci. 2025;116:1604-1615.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

23. TRACEWELL MA, Karlin JE, Barnada SM, McDuffie EL, et al
    Somatic p53 mutations that are markedly overrepresented in lung cancer confer resistance to ROS-induced cell death.
    Carcinogenesis. 2025 Jun 3:bgaf027. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

24. MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al
    Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
    Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
    PubMed         Abstract available
    
    
25. ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al
    ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.
    Clin Cancer Res. 2025;31:2162-2172.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

26. RAEISI N, Saber Tanha A, Aryana K, Jabbari Nooghabi A, et al
    Pulmonary Lymphangitis Carcinomatosis in Rapid Progressive Recurrent Pheochromocytoma: A Case Exhibiting the Peer Diagnostic Value of 99mTc-FAPI-46 and 99mTc-HYNIC-Octreotide Scans.
    Clin Nucl Med. 2025;50:e417-e418.
    PubMed         Abstract available
    
    
27. TAO X, Zhang Q, Li N, Wang S, et al
    Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study.
    Clin Nucl Med. 2025;50:577-587.
    PubMed         Abstract available
    
    
28. LIU G, Wang S, Du B, Li Y, et al
    PSMA and FDG PET/CT Findings for Differential Diagnosis of Bone Metastasis in a Patient With Synchronous Small-cell Lung Cancer and Prostate Cancer.
    Clin Nucl Med. 2025 Jun 5. doi: 10.1097/RLU.0000000000005915.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

29. QIU T, Hou F, Wu J, Wu Z, et al
    Concurrent spread through air spaces in dominant tumours impacts prognosis in synchronous multiple primary lung adenocarcinoma.
    Eur J Cardiothorac Surg. 2025;67:ezaf163.
    PubMed         Abstract available
    
    

    
    Int J Cancer

30. ZHONG R, Chu T, Xiong L, Shi C, et al
    Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study.
    Int J Cancer. 2025;157:549-558.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

31. TAHERI P, Golden A
    A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights.
    J Cancer Res Clin Oncol. 2025;151:180.
    PubMed         Abstract available
    
    
32. ZHAO X, Fu W
    Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.
    J Cancer Res Clin Oncol. 2025;151:182.
    PubMed         Abstract available
    
    

    
    J Clin Invest

33. LEE S, Park J, Cho S, Kim EJ, et al
    Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells.
    J Clin Invest. 2025;135:e180570.
    PubMed         Abstract available
    
    
34. DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al
    Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV.
    J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. FELIP E, Altorki N, Zhou C, Vallieres E, et al
    Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
    J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681.
    PubMed         Abstract available
    
    
36. HE J, Tsuboi M, Weder W, Chen KN, et al
    Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2025 Jun 2:101200JCO2500883. doi: 10.1200/JCO-25-00883.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

37. ZHANG J, Wang S, Li T, Liu X, et al
    RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.
    J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
    PubMed        
    
    

    
    J Thorac Oncol

38. PETERS S, Regan MM, Paz-Ares LG, Reck M, et al
    Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
    PubMed         Abstract available
    
    
39. MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al
    Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
    PubMed         Abstract available
    
    

    
    Lancet

40. PAZ-ARES L, Borghaei H, Liu SV, Peters S, et al
    Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011.
    PubMed         Abstract available
    
    

    
    Lung Cancer

41. THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
    Corrigendum to "A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers" [Lung Cancer 199 (2025) 108060].
    Lung Cancer. 2025;204:108488.
    PubMed        
    
    
42. MA Z, Zhang Y
    A Reply to comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
    Lung Cancer. 2025;204:108537.
    PubMed        
    
    
43. ONDER AH
    Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
    Lung Cancer. 2025;204:108536.
    PubMed        
    
    
44. ZHANG B, Zhang J
    Comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
    Lung Cancer. 2025;204:108515.
    PubMed        
    
    
45. AHMAD WKM, Bedau T, Wang Y, Michels S, et al
    Development and clinical validation of a prognostic algorithm for stroma-tumor ratio quantification in non-small cell lung cancer.
    Lung Cancer. 2025;205:108613.
    PubMed         Abstract available
    
    
46. DI LECCE C, Eccher S, Simbolo M, Cocomazzi A, et al
    ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR.
    Lung Cancer. 2025;205:108594.
    PubMed         Abstract available
    
    
47. LEIGHL NB, Trigo J, Park K, Lee SH, et al
    Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer.
    Lung Cancer. 2025;205:108579.
    PubMed         Abstract available
    
    
48. OKADA A, Sakata Y, Oya Y, Sakata S, et al
    Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
    Lung Cancer. 2025;204:108589.
    PubMed         Abstract available
    
    
49. TANAKA S, Nozaki K, Watanabe S, Yanagimura N, et al
    Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.
    Lung Cancer. 2025;204:108590.
    PubMed         Abstract available
    
    
50. RUAN Z, Zeng L, Zhang J, Qin H, et al
    Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma.
    Lung Cancer. 2025;204:108586.
    PubMed         Abstract available
    
    
51. CHEN T, Liu F
    Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.
    Lung Cancer. 2025;204:108588.
    PubMed         Abstract available
    
    
52. ROMA L, Chijioke O, Flury DV, Kocher GJ, et al
    Unusual relapse dynamics in EGFR-mutated lung adenocarcinoma uncovered by genomic profiling: Insights from a case report.
    Lung Cancer. 2025;204:108587.
    PubMed         Abstract available
    
    
53. WHEATLEY-PRICE P, Navani V, Pabani A, Routy B, et al
    Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT --> durvalumab in Canada: The RELEVANCE study.
    Lung Cancer. 2025;204:108583.
    PubMed         Abstract available
    
    
54. FACCHINETTI F, Camerini A, Bennati C, Bordi P, et al
    A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).
    Lung Cancer. 2025;204:108580.
    PubMed         Abstract available
    
    
55. EKLUND EA, Orgard M, Wallin D, Sayin SI, et al
    Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.
    Lung Cancer. 2025;204:108573.
    PubMed         Abstract available
    
    
56. YAMADA J, Hazama D, Fukui T, Yatani A, et al
    Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study.
    Lung Cancer. 2025;204:108556.
    PubMed         Abstract available
    
    
57. SHAO T, Yang J, Chen J, Zhang Y, et al
    Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis.
    Lung Cancer. 2025;204:108559.
    PubMed         Abstract available
    
    
58. SERNA-BLASCO R, Mediavilla-Medel P, Medina K, Sala MA, et al
    Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
    Lung Cancer. 2025;204:108550.
    PubMed         Abstract available
    
    
59. GUCKENBERGER M, Opitz I, Dellaporta T, Curioni-Fontecedro A, et al
    Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
    Lung Cancer. 2025;204:108553.
    PubMed         Abstract available
    
    
60. KIM D, Lee J, Jung M, Yim K, et al
    Whole slide image-level classification of malignant effusion cytology using clustering-constrained attention multiple instance learning.
    Lung Cancer. 2025;204:108552.
    PubMed         Abstract available
    
    
61. MURAT-ONANA ML, Ramalingam SS, Janne PA, Gray JE, et al
    EGFR mutation testing across the osimertinib clinical program.
    Lung Cancer. 2025;204:108549.
    PubMed         Abstract available
    
    
62. SUGAI M, Amino Y, Fujishima S, Nibuya K, et al
    Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.
    Lung Cancer. 2025;204:108555.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

63. POLONIO-ALCALA E, Auselle-Bosch S, Riesco-Llach G, Novales P, et al
    Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells.
    Lung Cancer (Auckl). 2025;16:57-72.
    PubMed         Abstract available
    
    

    
    N Engl J Med

64. LENTZ RJ, Frederick-Dyer K, Planz VB, Koyama T, et al
    Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
    N Engl J Med. 2025;392:2100-2112.
    PubMed         Abstract available
    
    
65. FORDE PM, Spicer JD, Provencio M, Mitsudomi T, et al
    Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931.
    PubMed         Abstract available
    
    
66. MOUNTZIOS G, Sun L, Cho BC, Demirci U, et al
    Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099.
    PubMed         Abstract available
    
    

    
    Nat Med

67. CASCONE T, Bonanno L, Guisier F, Insa A, et al
    Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
    Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746.
    PubMed         Abstract available
    
    

    
    PLoS Biol

68. ZHANG T, Wang S, Zhou Y, Jiao Z, et al
    Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes.
    PLoS Biol. 2025;23:e3002846.
    PubMed         Abstract available
    
    

    
    PLoS One

69. JIM JR, Rayed ME, Mridha MF, Nur K, et al
    XLLC-Net: A lightweight and explainable CNN for accurate lung cancer classification using histopathological images.
    PLoS One. 2025;20:e0322488.
    PubMed         Abstract available
    
    

    
    Thorax

70. CREAMER AW, Horst C, Prendecki R, Verghese P, et al
    Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening.
    Thorax. 2025 Jun 2:thorax-2024-222086. doi: 10.1136/thorax-2024-222086.
    PubMed         Abstract available
    
    
71. HAMMER MM
    Comparison of volume-based and diameter-based assessment of solid nodules in lung cancer screening.
    Thorax. 2025 Jun 2:thorax-2025-223295. doi: 10.1136/thorax-2025-223295.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.